^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HRD + BRCA wild-type

    i
    Other names: HRD, Homologous Recombination Deficiency, BRCA, Breast cancer, early onset
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    3ms
    A comparative analysis of tumor markers reveals EDA fibronectin as a promising target in high-grade serous ovarian cancer. (PubMed, J Ovarian Res)
    These findings highlight that EDA-FN is an excellent target for HGSOC, while CEA could serve as a potential target for MOC. Clinical investigations are warranted to evaluate innovative treatments in ovarian cancer targeting these antigens.
    Clinical • Journal • BRCA Biomarker
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • FN1 (Fibronectin 1)
    |
    HRD + BRCA wild-type
    11ms
    OVARD: A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation (clinicaltrials.gov)
    P=N/A, N=400, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HRD (Homologous Recombination Deficiency)
    |
    HRD • HRD + BRCA wild-type
    almost2years
    T Cell Exhaustion Correlates With Homologous Recombination And Determines Survival In High Grade Serous Ovarian Cancer. (ESGO 2024)
    Conclusion These results demonstrate an association between T-cell exhaustion and HRD. T-cell exhaustion is an independent predictor of disease outcome in HGSOC.
    PD(L)-1 Biomarker • BRCA Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • HRD (Homologous Recombination Deficiency) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    PD-L1 expression • HRD • HRD + BRCA wild-type • HAVCR2 expression
    |
    Myriad myChoice® CDx Plus
    2years
    Sponsor's Symposium (Takeda) What do we know so far for the maintenance of HRD/BRCAwt ovarian cancer patients? (ASGO 2023)
    Sponsored by Takeda
    Clinical
    |
    HRD + BRCA wild-type
    2years
    TITLE UNDERSTANDING CURRENT PRACTICES FOR THE MANAGEMENT OF ADVANCED EPITHELIAL HIGH-GRADE OVARIAN CANCER IN THE UK: INTERIM DATA FROM THE OC-NOW SURVEY (2023) (IGCS 2023)
    The analysis included 50 OC MDT members. Respondents were mainly based in England (84%; 42/50). Most HCPs (68%; 19/28) used the DESKTOP-III criteria to identify candidates for secondary cytoreduction, with up to 30% of patients considered as eligible in 85% (23/27) of centres.
    BRCA Biomarker • PARP Biomarker • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA wild-type • HRD + BRCA wild-type • BRCA mutation
    over2years
    Understanding Current Practices For The Management Of Advanced Epithelial High-Grade Ovarian Cancer In The UK: Interim Analysis From The OC-NOW Survey (2023) (ESGO 2023)
    Platinum-sensitive patients typically received PARPi maintenance therapy, irrespective of HRD status. Most HCPs used DESKTOP-III criteria to determine secondary debulking candidates at first relapse.
    BRCA Biomarker • PARP Biomarker • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA wild-type • HRD + BRCA wild-type • BRCA mutation
    over2years
    OVARD: A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation (clinicaltrials.gov)
    P=N/A, N=400, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HRD (Homologous Recombination Deficiency)
    |
    HRD • HRD + BRCA wild-type
    over2years
    OVARD: A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation (clinicaltrials.gov)
    P=N/A, N=400, Not yet recruiting, AstraZeneca
    New trial
    |
    HRD (Homologous Recombination Deficiency)
    |
    HRD • HRD + BRCA wild-type
    over2years
    DEB3 Should All HRD/BRCA WT Patients Be Treated with PARP+ Antiangiogenic Agents? (ESGO 2023)
    On the other hand , subgroup analyses of Paola 1 indicated a greater benefit for the combination of olaparib and bevacizumab in patients at lower risk of recurrence, i.e., patients without residual disease after primary debulking surgery. Several ongoing trials (e.g., NIRVANA-1, AGO-OVAR 28/ENGOT-ov57) are currently evaluating the contribution of adding bevacizumab to PARPi and will provide further evidence on this subject. Moreover, the magnitude of benefit from the combination could also depend on the location and type of HR gene mutations, and additional research is warranted to deepen our knowledge of the predictive role of the exact “causes” behind HR deficiency.
    Clinical • BRCA Biomarker • PARP Biomarker
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
    |
    HRD • BRCA wild-type • HRD + BRCA wild-type
    |
    Avastin (bevacizumab) • Lynparza (olaparib)
    over2years
    PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial. (PubMed, Eur J Cancer)
    A robust correlation between the Leuven HRD and Myriad test was observed. For HRD+ tumours, the academic Leuven HRD showed a similar difference in PFS and OS as the Myriad test.
    Journal • PARP Biomarker • BRCA Biomarker
    |
    TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    HRD • HRD + BRCA wild-type
    |
    Myriad myChoice® CDx Plus
    |
    Lynparza (olaparib)
    over2years
    Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials. (PubMed, World J Surg Oncol)
    The results suggest that PARPi have a meaningful clinical benefit in PSOC, HRD, BRACm, and also in HRP and PROC; however, the evidence is not sufficient to recommend their routine use and further studies are needed to expand their role in the HRP and PROC groups.
    Clinical • Retrospective data • Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA wild-type • HRD + BRCA wild-type • BRCA mutation
    over2years
    Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma. (PubMed, J Ovarian Res)
    The HRD status can be identified as an independent significance in Chinese HGSOC patients treated with first-line platinum-based chemotherapy.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    BRCA1 mutation • HRD • HRD + BRCA1 mutation • HRD + BRCA wild-type • High HRD score